Two faces of myeloid
How Pionyr intends to enhance the antitumor immune response
Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells.
Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) can weaken antitumor immunity and limit efficacy of checkpoint therapies.
However, a 2014 Cancer Cell paper by founder Max Krummel and his colleagues at University of California San Francisco demonstrated that at least one subtype